Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Part of paid clinical trials in New York, New York.

Sponsor
Weill Medical College of Cornell University
Study ID
NCT04631744
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily

Study Details

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.

Key Dates

Start date
Mar 3, 2021
Status verified
Apr 2026
Primary completion
May 12, 2025
Completion
Nov 9, 2025

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib Arm

Primary Outcome Measure

Median Radiographic Progression-free Survival (rPFS) Using Kaplan-Meier Methodology [ Time Frame: From initiation of treatment to minimum of radiographic progression, approximately 6 months. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Weill Cornell MedicineNew YorkNew York10065-

Find similar trials in New York, NY

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Weill Cornell Medicine· New York, NY

Related Studies